A natural biological process that progressively weakens the immune system in older adults is drawing heightened attention from researchers as the global population ages. This phenomenon, known as immunosenescence, describes the gradual deterioration of immune function that accompanies aging.
The condition typically begins to manifest between the ages of 50 and 60 and accelerates markedly after age 70. Central to this decline is the shrinking of the thymus, an organ that starts to atrophy at puberty. By age 70, the thymus has largely been replaced by fatty tissue and produces only about 10 percent of its youthful output of immune cells. Alongside this decline, the diversity of B cells — which produce antibodies — also falls, leading to weaker antibody responses.
Although the number of memory T cells increases with age, their diversity diminishes, resulting in a poorer ability to respond to new pathogens and vaccines. Scientists have recognized immunosenescence for decades, with early studies documenting how thymic involution leaves older adults with fewer naive T cells to fight new infections.
The Measurable Consequences of Immune Aging
The impact of immunosenescence is quantifiable. For example, the influenza vaccine is only 30 to 50 percent effective in adults over 65, compared to 70 to 90 percent in younger adults.
The COVID-19 pandemic starkly illustrated this vulnerability: according to Centers for Disease Control and Prevention data from 2020 to 2022, people aged 65 and older accounted for 80 percent of COVID-19 deaths in the United States. Immunosenescence does not occur in isolation. A related condition called inflammaging — chronic low-grade inflammation that increases with age — compounds the problem.
This persistent inflammation contributes to a range of serious diseases, including cardiovascular disease, type 2 diabetes, and Alzheimer’s disease. Researchers in the 1990s began linking age-related immune decline to inflammaging, recognizing that together they create a compounded vulnerability that extends well beyond seasonal flu.
The scale of the issue is growing rapidly. The global population aged 65 and over stood at 761 million in 2021, according to World Bank data, and is projected to reach 1.6 billion by 2050. This demographic shift makes understanding and addressing immunosenescence a pressing public health priority.
Widespread vaccination campaigns in the 2000s highlighted how much age blunts immune response, as older adults consistently showed weaker antibody production after standard shots. That observation prompted the development of specialized vaccines, including a high-dose influenza vaccine approved for people over 65 in 2009.
Emerging Strategies to Counter Immune Decline
Several strategies have been developed to counteract immunosenescence. Vaccination with adjuvants has shown promise; the high-dose flu vaccine Fluzone, approved in 2009 for adults 65 and older, is one example. Regular exercise and adequate nutrition, including supplementation with zinc and vitamin D, may also help support immune function in older adults.
Ongoing research is exploring ways to rejuvenate the immune system. Studies are investigating caloric restriction, the drug metformin, and interleukin-7 therapy as potential interventions.
The COVID-19 pandemic brought the issue into sharp public view, as older adults experienced the overwhelming share of severe outcomes. What matters now is the accelerating demographic shift: a large and growing portion of the world’s population is entering the age range where immunosenescence takes hold. This means more people will face higher risks from common infections and diminished protection from routine vaccines.
Researchers are exploring ways to slow or reverse immune aging, including exercise, targeted nutrition, and experimental therapies that aim to rejuvenate the thymus. The urgency of this work grows with each passing year as the number of older adults continues to rise globally.
